The following is a summary of “Anticoagulation and Antiplatelet Therapy for Atrial Fibrillation and Stable Coronary Disease: ...

Penumbra's thrombectomy growth and new products show promise, but high valuation at 7x 2025 revenue tempers appeal for GARP ...

With no differences between single or dual antiplatelet therapy or anticoagulants at 6 months, an RCT is warranted for ...

William Blair raised their Q3 2026 earnings per share estimates for Bristol-Myers Squibb in a note issued to investors on Tuesday, March 11th. William Blair analyst M. Phipps now anticipates that the ...